Johnson & Johnson struck an agreement to acquire Ollin Biosciences, aiming to add a late-stage bispecific antibody program for serious retinal diseases to its ophthalmology pipeline. The deal also includes Blackstone Life Sciences’ funding support for Phase 3 development of OLN324, positioning the acquisition as a platform build alongside J&J’s existing retina portfolio.